20/20 GeneSystems

Growth Stage

Diagnostic Testing for COVID-19 & Cancer

Overview

Raised to Date: Raised: $2,903,017

Total Commitments ($USD)

Platform

StartEngine

Start Date

01/08/2020

Close Date

06/27/2021

Min. Goal

$502

Max. Goal

$14,700,000

Min. Investment

$502

Security Type

Equity - Preferred

Series

Series A

Funding Type

RegA+

Price Per Share

$4.40

Pre-Money Valuation

$38,500,000

Venture Capital Investors:

Rolling Commitments ($USD)

Status
Funded
Reporting Date

06/30/2021

Days Remaining
Funded
% of Min. Goal

578,751%

% of Max. Goal

20%

Likelihood of Max
Funded
Avg. Daily Raise

$5,416

# of Investors

2,815

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Location

Rockville, Maryland

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Business Type

Growth

SEC Filing

Company Website

20/20 GeneSystems, with a pre-money valuation of $38.5 million, is raising funds on StartEngine through Reg A+ crowdfunding. It is a diagnostics company with a successful track record in cancer detection with its AI-powered multi-cancer blood test, OneTest. The company has recently launched CoronaCheck, its FDA authorized antibody lab test for COVID-19 antibodies. 20/20 GeneSystems was founded by Jonathan Cohen in 2000. The current round of funding has a round size of $14,700,000, and the proceeds will be used for sales and marketing, research and development, intellectual property development and protection, and cybersecurity and patient privacy protections. 20/20 GeneSystems has already sold over 70,000 COVID-19 antibody tests since its launch in March 2020, and year-over-year revenues have grown by over 600%.

Balance Sheet

Cash and Cash Equivalents

$636,018

Investment Securities

$1,647,806

Accounts and Notes Receivable

$32,498

Property, Plant and Equipment (PP&E)

$48,924
Total Assets

$3,125,886

Accounts Payable & Accrued Liabilities

$898,785

Long Term Debt

$0

Total Liabilities

$976,560

Total Stockholders' Equity

$2,149,326
Total Liabilities and Equity

$3,125,886

Statement of Comprehensive Income Information

Total Revenues

$288,300

Costs & Expenses Applicable to Rev

$263,917

Depreciation and Amortization

$23,550
Net Income

$-2,425,338

Earnings Per Share - Basic

$-0.51

Earnings Per Share - Diluted

$-0.51
Auditor: Dbbmckennon
Financials as of: 01/08/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
20/20 GeneSystems 12/21/2022 StartEngine $58,400,000 $232,704 Convertible Note Funded RegCF
20/20 GeneSystems 06/27/2021 StartEngine $38,500,000 $2,903,017 Equity - Preferred Funded RegA+
20/20 GeneSystems 11/01/2020 SeedInvest $38,500,000 $3,792,229 Equity - Preferred Funded RegA+
20/20 GeneSystems 12/14/2017 Microventures $23,000,000 $1,064,807 Equity - Preferred Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
20/20 GeneSystems on StartEngine
$
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $38,500,000
Invest in a different round for this company? Use my investment date to determine which raise I invested in.

Follow company

Follow 20/20 GeneSystems on StartEngine
View on StartEngine (Closed)
Deal Analytics